Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
NCT04179084Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2019
- Primary completion
- Mar 2020
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and sintilimab in colorectal cancer (CRC), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
fruquintinibsintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04179084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179084.